DTIL vs PATH · rev $68.7M vs P/E 19, rev $1.61B
Precision BioSciences Inc (DTIL) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Precision BioSciences Inc (DTIL) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported DTIL revenue for 2024-12-31 was $68.7M. Net income was $7.2M. Revenue was up 41.0% from 2023-12-31 to 2024-12-31. DTIL currently screens at market cap $48.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
DTIL currently screens at market cap $48.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the DTIL and PATH stock pages for the full models.
Not investment advice.